raffnhall@gmail.com
(806) 744-8477
3404 I-27 Frontage Rd, Lubbock, TX 79404
Raff and Hall Logo
DHEA _ Pregnenolone Capsules
DHEA _ Pregnenolone Capsules
503A

DHEA / Pregnenolone Capsules

See Product Details

Start your order
DHEA _ Pregnenolone Capsules
DHEA _ Pregnenolone Capsules
503A

DHEA / Pregnenolone Capsules

See Product Details
Order
DHEA _ Pregnenolone Capsules
DHEA _ Pregnenolone Capsules
503A

DHEA / Pregnenolone Capsules

See Product Details

25 mg / 25 mg25 mg / 50 mg50 mg / 100 mg

DHEA _ Pregnenolone Capsules

$100.00

Add to cart
Buy Now
Order

Product Overview

This product is available solely through our 503A Compounding Pharmacy, ensuring personalized care and precision in every order. Please note that a valid prescription is required for purchase. If you do not have an account, please contact us.

DHEA / Pregnenolone Capsule (Immediate Release / Slow Release) (Each)

25 mg / 25 mg25 mg / 50 mg50 mg / 100 mg

DHEA (Dehydroepiandrosterone) and Pregnenolone Capsules are dietary supplements that support hormonal balance in the body. DHEA is a precursor hormone that helps the body produce androgens and estrogens, while pregnenolone plays a role in the production of several other hormones, including progesterone and cortisol. These capsules are often used to support energy levels, mood, cognitive function, and overall hormonal health, especially during periods of stress, aging, or hormonal imbalance.

These capsules work by supplying the body with precursors needed to produce important hormones. Together, they may help regulate stress responses, enhance mental clarity, and support immune and reproductive functions by ensuring that the hormonal pathways have the building blocks they need to function properly.

They are also not recommended for individuals with liver disease, adrenal tumors, or those taking certain medications without medical supervision. Always consult a healthcare provider before starting these supplements, especially if you have a history of hormonal disorders or are on other hormone-based treatments.

Some people may experience mild side effects such as acne, headaches, changes in menstrual flow, or mood swings when using DHEA and pregnenolone capsules. High doses or prolonged use could lead to hormone imbalances, increased hair growth, or breast tenderness. If you notice any unusual symptoms or worsening of pre-existing conditions, it’s important to seek medical advice promptly.

These supplements are generally not recommended during pregnancy or breastfeeding, as their effects on fetal development and nursing infants have not been well studied. Hormonal changes caused by DHEA and pregnenolone could potentially impact both the mother and baby. It’s best to consult with a healthcare provider before using these supplements while trying to conceive or during the nursing period.

Store this medication in its original container at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond-use date. Do not flush unused medications or pour down a sink or drain.

  1. Kroboth PD, Slalek FS, Pittenger AL et al. DHEA and DHEA-S: a review. J Clin Pharmacol 1999;39:327-348.
  2. Skolnick AA. Medical news and perspectives-scientific verdict still out on DHEA. JAMA 1996;276:1365-1367.
  3. Kreider RB. Dietary supplements and the promotion of muscle growth with resistance exercise. Sports Med 1999;27:97-110.
  4. Marx CE, Keefe RSE, et al. Proof-of-Concept Trial with the Neurosteroid Pregnenolone Targeting Cognitive and Negative Symptoms in Schizophrenia. Neuropsychopharmacology. 2009 Jul; 34(8): 1885–1903.
  5. Vallée M, Mayo W, Moal ML. Role of pregnenolone, dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging. Brain Res Brain Res Rev. 2001 Nov;37(1-3):301-12.
  6. Murugan S, Jakka P, Namani S , Mujumdar V, Radhakrishnan G. The neurosteroid, pregnenolone promotes degradation of key proteins in the innate immune signalling to suppress inflammation. 2019;294(12):4596-4607.
  7. Michael Ritsner, Rachel Maayan, Anatoly Gibel, Abraham Weizman. Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjects. Eur Neuropsychopharmacol. 2007;17(5):358-65.
  8. Marx CE, Stevens RD, Shampine LJ, et al. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology. 2006;31(6):1249-63.
  9. George MS, Guidotti A, Rubinow D, Pan B, Mikalauskas K, Post RM. CSF neuroactive steroids in affective disorders: pregnenolone, progesterone, and DBI. Biol Psychiatry. 1994;35(10):775-80.
  10. Weill-Engerer S, David JP, Sazdovitch V. Neurosteroid quantification in human brain regions: comparison between Alzheimer’s and nondemented patients. J Clin Endocrinol Metab. 2002;87(11):5138-43.
  11. Brown ES, Park J,1 Marx CE, et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Pregnenolone for Bipolar Depression. Neuropsychopharmacology. 2014; 39(12): 2867–2873.
  12. Araneo BA, Ryu SY, Barton S, et al. Dehydroepiandrosterone reduces progressive dermal ischemia caused by thermal injury. J Surg Res 1995;59:250-262.
  13. Jesse Rl, Loesser K, Eich DM, et al. Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. Ann N Y Acad Sci 1995;774:281-290.
  14. 25801
  15. Schumacher M, Robel P, Baulieu EE. Development and regeneration of the nervous system: a role for neurosteroids. Dev Neurosci. 1996;18(1-2):6-21.
  16. Mellon SH. Neurosteroid regulation of CNS development. Pharmacol Ther. 2007;116(1):107–124.
  17. Baulieu EE, Robel P, Schumacher M. Neurosteroids: beginning of the story. Int Rev Neurobiol. 2001;46:1-32.
  18. Baulieu EE. Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog Horm Res. 1997;52:1-32.
  19. Fontaine-Lenoir V, Chambraud B, Fellous A, David S, Duchossoy Y, Baulieu EE, Robel P. Microtubule-associated protein 2 (MAP2) is a neurosteroid receptor. Proc Natl Acad Sci USA. 2006;103(12):4711–4716.
  20. Wang M. Neurosteroids and GABA-A Receptor Function. Front Endocrinol (Lausanne). 2011;2:44.
  21. Akk G, Bracamontes J, Steinbach JH. Pregnenolone sulfate block of GABAA receptors: mechanism and involvement of a residue in the M2 region of the α subunit. J Physiol. 2001;532(Pt 3):673–684.
  22. Pertwee R.G. (2015) Endocannabinoids and Their Pharmacological Actions. In: Pertwee R. (eds) Endocannabinoids. Handbook of Experimental Pharmacology, vol 231.
  23. Romieu P, Martin-Fardon R, Bowen WD, Maurice T. σ1 Receptor-Related Neuroactive Steroids Modulate Cocaine-Induced Reward. J Neurosci. 2003;23(9):3572–3576.
  24. Kliewer SA, Lehmann JM, Milburn MV, Willson TM. The PPARs and PXRs: nuclear xenobiotic receptors that define novel hormone signaling pathways. Recent Prog Horm Res. 1999;54:345-67.
  25. Ma Y, Liu D. Activation of Pregnane X Receptor by Pregnenolone 16 α-carbonitrile Prevents High-Fat Diet-Induced Obesity in AKR/J Mice. PLoS One. 2012;7(6):e38734.
  26. Katz S, Morales AJ. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DS) as therapeutic options in menopause. Semin Reprod Endocrinol 1998;16:161-170.
  27. Rosenfield RL. Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999;28:265-293.
  28. Wellman M, Shane-McWhorter L, Orlando PL et al. The role of dehydroepiandrosterone in diabetes mellitus. Pharmacotherapy 1999;19:582-591.
  29. Centurelli MA, Abate MA. The role of dehydroepiandrosterone in AIDS. Ann Pharmacother 1997;31:639-642.
  30. Russo J, Russo IH. The Role of Estrogen in the Initation of Brest Cancer. J Steroid Biochem Mol Biol. 2006;102(1-5)89–96.
  31. Yang B, Chen R, Liang X, Shi J, Wu X, Zhang Z, Chen X. Estrogen Enhances Endometrial Cancer Cells Proliferation by Upregulation of Prohibitin. J Cancer. 2019; 10(7):1616-1621.
  32. Mungenast F, Thalhammer T. Estrogen Biosynthesis and Action in Ovarian Cancer. Front Endocrinol (Lausanne). 2014;5:192.
  33. Bosland MC. The Role of Estrogens in Prostate Carcinogenesis: A Rationale for Chemoprevention. Rev Urol. 2005;7(Suppl 3):S4–S10.
  34. Deroo BJ, Korach KS. Estrogen receptors and human disease. J Clin Invest. 2006;116(3):561–570.
  35. Serdar E. Bulun SE, Monsavais D, Pavone ME, Dyson M, Xue Q, Attar E, Tokunaga H, Su EJ. Role of Estrogen Receptor-β in Endometriosis. Nat Med. 2012;18(7):1016–1018.
  36. Howard BV, Rossouw JE. Estrogens and Cardiovascular Disease Risk Revisited: the Women’s Health Initiative. Curr Opin Lipidol. 2013;24(6):493–499.
  37. Gilbert EL, Ryan MJ. Estrogen in Cardiovascular Disease during Systemic Lupus Erythematosus. Clin Ther. 2014;36(12):1901–1912.
  38. Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O, Mikkola TS. Use of postmenopausal hormone therapy and risk of Alzheimer’s disease in Finland: nationwide case-control study. BMJ. 2019;364:l665.
  39. Velíšková J, Jesus GD, Kaur R, and Velíšek L. Females, their estrogens and seizures. Epilepsia. 2010; 51(Suppl 3):141–144.
  40. Vacheron-Trystram MN, Cheref S, Gauillard J, Plas J. [A case report of mania precipitated by use of DHEA]. Encephale. 2002;28(6 Pt 1):563-566.
  41. Dean CE. Prasterone (DHEA) and mania. Ann Pharmacother. 2000;34(12):1419-22.
  42. Pure Encapsulations® pregnenolone 30mg capsules package insert. 2016.
  43. Randel A. AACE Releases Guidelines for Menopausal Hormone Therapy. Am Fam Physician. 2012;86(9):864-868.
  44. Mueck AO, Seeger H. Smoking, estradiol metabolism and hormone replacement therapy. Curr Med Chem Cardiovasc Hematol Agents. 2005;3(1):45-54.
  45. Svartberg J, Jorde R. Endogenous testosterone levels and smoking in men. The fifth Tromsø study. Int J Androl. 2007;30(3):137-43.
  46. Kroboth PD, Slalek FS, Pittenger AL et al. DHEA and DHEA-S: a review. J Clin Pharmacol 1999;39:327—48.
  47. Robbers JE, Tyler VE. Tyler’s Herbs of Choice: the Therapeutic Use of Phytomedicinals. Binghamton NY: Haworth Herbal Press, Inc.; 1999.
  48. German Commission E. Saw Palmetto berry, Sabal fructus, monograph Published March 2, 1989 and revised January 17, 1991. In: Blumenthal, M et al ., eds. The complete German Commission E Monographs -Therapeutic Guide to Alternative Medicines. Boston MA: Int
  49. Robinson B, Cutolo M. Should dehydroepiandrosterone replacement therapy be provided with chronic glucocorticoids? Rheumatology 1999;38:488—95.
  50. Jesse Rl, Loesser K, Eich DM et al. Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. Ann NY Acad Sci 1995;774:281—90.
  51. Premarin® (conjugated estrogens, equine) package insert. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2003 Jul.
  52. Wellman M, Shane-McWhorter L, Orlando PL et al. The role of dehydroepiandrosterone in diabetes mellitus. Pharmacotherapy 1999;19:582—91.
  53. Frye RF, Kroboth PD, Folan MM, et al. Effect of DHEA on CYP3A4-mediated metabolism of triazolam (Abstract PI-82). Clin Pharmacol Ther 2000;67:109.
  54. Androderm® (testosterone transdermal system) package insert. Corona, CA: Watson Pharma, Inc.; 1999 Jan.
  55. Aldercreutz H, Mazur W. Phyto-estrogens and western diseases. Annals of Medicine 1997;29:95—120.
 

Related medications

503A vs 503B

  • 503A pharmacies compound products for specific patients whose prescriptions are sent by their healthcare provider.
  • 503B outsourcing facilities compound products on a larger scale (bulk amounts) for healthcare providers to have on hand and administer to patients in their offices.
Learn More

Frequently asked questions

Our team of experts has the answers you're looking for.

A clinical pharmacist cannot recommend a specific doctor. Because we are licensed in Arizona, California, New Mexico, Texas, we can accept prescriptions from many licensed prescribers if the prescription is written within their scope of practice and with a valid patient-practitioner relationship.

*Licensing is subject to change.

Each injectable IV product will have the osmolarity listed on the label located on the vial.

Given the vastness and uniqueness of individualized compounded formulations, it is impossible to list every potential compound we offer. To inquire if we currently carry or can compound your prescription, please fill out the form located on our Contact page or call us at (806) 744-8477.

We source all our medications and active pharmaceutical ingredients from FDA-registered suppliers and manufacturers.

We're licensed to ship Arizona, California, New Mexico and Texas.

We ship orders directly to you, quickly and discreetly.

Learn More

Ready to get started?

Contact Us